Taking peoplePhase 4
Continuing ovulation induction with letrozole versus switching to gonadotropins in women with polycystic ovary syndrome (MOVIN-II study)
Key facts
- Who runs it
- Amsterdam UMC Stichting
- Where
- Netherlands33 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 816 people, planned
- Started
- 1 Aug 2025
- Expected to end
- 1 Jun 2030
- Type of study
- Interventional
- Record updated
- 4 September 2026
Who can take part
- Age
- 18 years to 64 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Couples or single women with childwish
- Diagnosed PCOS (normogonadotropic anovulation with hyperandrogenaemia (diagnosed clinically by the presence of excessive acne, androgenic alopecia, or hirsutism or by elevated serum levels of total, bioavailable, or free testosterone or dehydroepiandrosterone sulfate) or polycystic ovaries on ultrasound)
- Age 18-42 years
- Ovulatory for six cycles on letrozole treatment
Who cannot take part
- Additional contra-indications reported in the SPC are: Hypersensitivity to the active substance, during pregnancy and breast feeding
- Total motile sperm count (VCM) < 3 million
- Major medical morbidity (e.g. poorly controlled Type I or Type II diabetes, known liver disease or dysfunction based on serum liver enzyme testing, renal disease or abnormal serum renal function)
- Contra-indication to letrozole
- Known bilateral fallopian tube pathology or occlusion (patients with at least one patent fallopian tube are eligible)
- Inability to give informed consent
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To determine the clinical efficacy of continuing ovulation induction with letrozole versus switching to ovarian stimulation with gonadotropins, in terms of cumulative live birth rate improvement
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Fit questions
- Built from 2024-519354-36-00, who can take part
- Record updated
- 4 September 2026